Paquinimod

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Paquinimod
Accession Number
DB13118  (DB05901)
Type
Small Molecule
Groups
Investigational
Description

Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease. The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. Current treatments of SLE are NSAID (nonsteroidal anti-inflammatory drugs), corticosteroids, antimalarians or cytotoxic drugs like for example Cyclophosphamide. The autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses.

Structure
Thumb
Synonyms
Not Available
External IDs
ABR-215757
Categories
Not Available
UNII
HB76GLG27V
CAS number
248282-01-1
Weight
Average: 350.418
Monoisotopic: 350.163042576
Chemical Formula
C21H22N2O3
InChI Key
DIKSYHCCYVYKRO-UHFFFAOYSA-N
InChI
InChI=1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,24H,4-5H2,1-3H3
IUPAC Name
N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
SMILES
CCN(C(=O)C1=C(O)C2=C(CC)C=CC=C2N(C)C1=O)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Paquinimod is combined with Anthrax immune globulin human.
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Paquinimod is combined with Bacillus calmette-guerin substrain connaught live antigen.
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Paquinimod is combined with Bacillus calmette-guerin substrain tice live antigen.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Paquinimod.
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Paquinimod is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Paquinimod is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Paquinimod.
FingolimodPaquinimod may increase the immunosuppressive activities of Fingolimod.
G17DTThe risk or severity of adverse effects can be increased when Paquinimod is combined with G17DT.
GI-5005The risk or severity of adverse effects can be increased when Paquinimod is combined with GI-5005.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
54684617
PubChem Substance
347829241
ChemSpider
11444964
ChEMBL
CHEMBL67776

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedBasic ScienceSystemic Lupus Erythematosus (SLE)1
2CompletedTreatmentSclerosis, Progressive Systemic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0653 mg/mLALOGPS
logP2.74ALOGPS
logP2.91ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)6.28ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.85 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity102.15 m3·mol-1ChemAxon
Polarizability37.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Aromatic anilides
Alternative Parents
Quinoline-3-carboxamides / Hydroquinolones / Hydroxyquinolines / Hydroquinolines / Pyridinecarboxylic acids and derivatives / Hydroxypyridines / Pyridinones / Tertiary carboxylic acid amides / Vinylogous acids / Vinylogous amides
show 7 more
Substituents
Aromatic anilide / Quinoline-3-carboxamide / Dihydroquinolone / Hydroxyquinoline / Dihydroquinoline / Quinoline / Pyridine carboxylic acid or derivatives / Hydroxypyridine / Pyridinone / Pyridine
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 21:20 / Updated on August 02, 2018 06:48